Samsung Bioepis Revenue and Competitors

Location

$668M

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • Samsung Bioepis's estimated annual revenue is currently $253.7M per year.(i)
  • Samsung Bioepis's estimated revenue per employee is $321,600
  • Samsung Bioepis's total funding is $668M.

Employee Data

  • Samsung Bioepis has 789 Employees.(i)
  • Samsung Bioepis grew their employee count by 5% last year.

Samsung Bioepis's People

NameTitleEmail/Phone
1
VPReveal Email/Phone
2
Head US Corporate DevelopmentReveal Email/Phone
3
Director Corporate FinanceReveal Email/Phone
4
Senior Manager Corporate FinanceReveal Email/Phone
5
Human Resources ManagerReveal Email/Phone
6
Senior Manager Supply PlanningReveal Email/Phone
7
Principal ScientistReveal Email/Phone
8
ScientistReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$46.2M2305%N/AN/A
#2
$43.8M21821%N/AN/A
#3
$57.1M28426%N/AN/A
#4
$24.5M1223%N/AN/A
#5
$52.9M26313%N/AN/A
#6
$24.7M12313%N/AN/A
#7
$1.8M180%$114.3MN/A
#8
$7.2M36-20%N/AN/A
#9
$13.7M68-7%N/AN/A
#10
$7.6M39-13%$123.9MN/A
Add Company

What Is Samsung Bioepis?

Established in 2012, Samsung Bioepis is a biopharmaceutical company committed to realizing healthcare that is accessible to everyone. Through innovations in product development and a firm commitment to quality, Samsung Bioepis aims to become the world's leading biopharmaceutical company. Samsung Bioepis continues to advance a broad pipeline of biosimilar candidates that cover a spectrum of therapeutic areas, including immunology, oncology and ophthalmology. Samsung Bioepis is a joint venture between Samsung BioLogics and Biogen. For more information, please visit: www.samsungbioepis.com.

keywords:N/A

$668M

Total Funding

789

Number of Employees

$253.7M

Revenue (est)

5%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Samsung Bioepis News

2022-04-20 - Amgen Releases Positive Phase 3 Results for Stelara Biosimilar

In addition to Amgen, Formycon, Samsung Bioepis, Bio-Thera Solutions, Hikma Pharmaceuticals, Alvotech, BioFactura, and NeuClone are in the...

2022-04-20 - Biogen : Completes Sale of Equity Stake in Biosimilar Joint Venture to Samsung Biologics for $2.3 Billion

Biogen has completed the sale of the company's equity stake in the Samsung Bioepis joint venture to Samsung Biologics for a total...

2022-03-30 - Samsung Bioepis buyout to bolster Samsung Biologics’ portfolio: CEO

INCHEON -- With the buyout of Samsung Bioepis' stake, Samsung Biologics will become a global bio company based on the three pillars of...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$35M7899%N/A
#2
$243M7898%N/A
#3
$298.2M789-63%N/A
#4
$160.2M78912%N/A
#5
$277.6M790N/AN/A